Secukinumab Biosimilar(Celltrion)

司库奇尤单抗生物类似药(Celltrion)

Report date: 2026/02/24 20:00:16

Base Information

Drug NameSecukinumab Biosimilar(Celltrion)

Drug Alias NameCT-P55

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionInterleukin 17A inhibitors

TargetsInterleukin 17A

Therapy Area/IndicationsPlaque psoriasisMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryPolandSouth KoreaJapan

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesCelltrion Inc

China Registration ClassN/A

Active CompaniesCelltrion Inc

Inactive CompaniesN/A

Active IndicationsPlaque psoriasisMultiple Sclerosis

Inactive IndicationsN/A

ATC CodeL04AC10